Denali Therapeutics (DNLI) Swings To Q3 Profit, Is The Upside Already Priced In?
Denali Therapeutics (DNLI) just flipped its latest quarter from a loss to a profit. The company reported US$17.78 million in revenue and net income of US$70.13 million for the third quarter of 2026.
The Q3 swing into profit has come alongside mixed trading in Denali Therapeutics, with the share price gaining 3.34% on the day of the release and a 1-year total shareholder return of 30.63%, even as the 3-year total shareholder return is down 8.20% and the 5-year figure is down 63.21%.
Scan other potential turnaround stories alongside Denali Therapeutics by checking our hand picked list of 19 high quality undiscovered gems in the market right now.
After a sharp quarterly profit and a strong 1 year run, Denali Therapeutics now raises a tougher question for new money: Does the current price still offer enough potential upside to justify the risk profile investors face?
Most Popular Narrative: 45% Undervalued
On the most followed view of Denali Therapeutics, the stock last closed at $19.49 compared with a narrative fair value estimate of $35.44. This puts the current debate squarely on how much of the pipeline story is already reflected in the price.
The enzyme transport vehicle franchise targets multiple lysosomal storage disorders where biologics are already an accepted treatment class. Denali Therapeutics expects each program to represent several hundred million dollars or more in potential annual market opportunity, which can influence long term revenue diversification and earnings resilience.
See why 1 investors see Denali Therapeutics as 45% undervalued.
Result: Fair Value of $35.44 (UNDERVALUED)
Still, the Denali Therapeutics story can change quickly if AVLAYAH prescriptions flatten in that small Hunter syndrome pool or if Alzheimer’s trials deliver weak or delayed data.
Find out about the key risks to this Denali Therapeutics narrative.
Another View: SWS DCF Checks The Optimism
The narrative fair value for Denali Therapeutics points to upside, yet the SWS DCF model tells a cooler story. On that framework, DNLI at $19.49 sits above an estimated future cash flow value of $18.11, which leans toward overvalued. Which set of assumptions do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 34 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Curious whether this upbeat Denali Therapeutics story really lines up with the underlying risk and reward trade off? Move quickly from headline impressions to your own view by weighing the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Denali Therapeutics?
If you stop with Denali Therapeutics, you only see one chapter. Broaden your watchlist and let fresh ideas compete for your next dollar.
- Jump on potential value gaps by scanning our 34 high quality undervalued stocks that pair quality fundamentals with compressed expectations.
- Strengthen your income stream by reviewing 4 dividend fortresses that combine robust payouts with disciplined financial profiles.
- Guard your capital more tightly by focusing on 30 resilient stocks with low risk scores that score well on resilience and downside protection.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com